Search results
Johnson & Johnson to acquire Proteologix for $850 million By Investing.com
Investing.com· 1 day agoJohnson & Johnson (NYSE: JNJ) announced it will acquire biotechnology firm Proteologix, Inc. for...
Johnson & Johnson Insiders Sell US$6.8m Of Stock, Possibly Signalling Caution
Simply Wall St. via Yahoo Finance· 1 hour agoThe fact that multiple Johnson & Johnson (NYSE:JNJ) insiders offloaded a considerable amount of...
Johnson & Johnson is selling off its stake in the maker of Tylenol and Band-Aids
Quartz· 4 days agoMorgan in exchange for its debt. Johnson & Johnson first announced that it was splitting its...
J&J-Backed Startup Rapport Files for US IPO
US News & World Report· 2 hours agoUS News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health conditions, and find news you can use in politics, business, health, and education.
Johnson & Johnson Strikes $850 Million Deal to Boost Dermatology Portfolio
Morningstar· 1 day agoJohnson & Johnson has agreed to buy privately-held biotechnology company Proteologix for an initial $850 million in cash in a deal that bolsters the healthcare ...
Johnson & Johnson looks to sell off stake in Kenvue
NJBIZ· 3 days agoJohnson & Johnson is looking to offload any remaining stake in its consumer health spinoff, Kenvue. In a May 13 filing with the U.S. Securities and...
Dow closes above 40,000 for first time, notching new milestone
CBS News· 3 hours agoThe index's listed companies include Apple, Intel and Microsoft among tech players, while the...
Undrafted Millard Bradford Has Chance To Steal A Spot In New Orleans Saints Secondary
Sports Illustrated· 3 hours agoThe scouting department of the New Orleans Saints has done a fine job at finding collegiate talent...
Johnson & Johnson is selling its remaining Kenvue shares
Morningstar· 4 days agoJohnson & Johnson is selling its remaining shares in Kenvue Inc., the consumer-health business that it spun out last year. The company will exchange the ...
Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M
Benzinga via Yahoo Finance· 1 day agoThursday, Johnson & Johnson (NYSE:JNJ) agreed to acquire Proteologix Inc., a privately held...